Life Sciences Tools and Services
Company Overview of Adaptive Biotechnologies Corporation
Adaptive Biotechnologies Corporation is engaged in combining high-throughput sequencing and expert bioinformatics to profile T-cell and B-cell receptors. The company offers immunosequencing platform to laboratories around the world to drive research in cancer and other immune-mediated diseases. It also translates immunosequencing discoveries into clinical diagnostics and therapeutic development to improve patient care. Adaptive Biotechnologies Corporation has a strategic research agreement with Argos Therapeutics, Inc. Adaptive Biotechnologies Corporation was formerly known as Adaptive TCR Corporation and changed its name to Adaptive Biotechnologies Corporation in January 2012. The company w...
1551 Eastlake Avenue East
Seattle, WA 98102
Founded in 2009
Key Executives for Adaptive Biotechnologies Corporation
Co-Founder, Chief Executive Officer, President and Director
Co-Founder, Head of Innovation & Director
Chief Financial Officer and Director
Senior VP & General Counsel
Compensation as of Fiscal Year 2017.
Adaptive Biotechnologies Corporation Key Developments
Adaptive Biotechnologies Announces Management Changes
Jul 26 17
Adaptive Biotechnologies announced the appointment of Mr. Gene DeFelice to SVP and General Counsel, and Dr. Alexandra Snyder to Translational Medicine Lead for Adaptive Research. Both Mr. DeFelice and Dr. Snyder bring significant experience that will provide strategic and scientific guidance to the existing and future products and services that Adaptive provides. Mr. DeFelice has over 30 years of legal experience and over 20 years in healthcare, including diagnostics, biotechnology, pharmaceuticals, and medical devices. Having served as General Counsel for several public healthcare and technology companies, including a role as primary counsel at Roche Diagnostics, Mr. DeFelice will join the Executive Team to implement a legal infrastructure that prepares Adaptive for strategic decision-making to lead in the rapidly expanding market for clinical applications of NGS technologies.
Adaptive Biotechnologies Announces a Collaboration with Janssen Biotech to Use the clonoSEQ Assay to Measure Minimal Residual Disease in Ongoing and Future DARZALEX Multiple Myeloma Trials
Jun 21 17
Adaptive Biotechnologies announced it has partnered with Janssen Biotech Inc. to utilize Adaptive's NGS-based clonoSEQ Assay for measuring minimal residual disease (MRD) in patients with Multiple Myeloma (MM) who have been treated with DARZALEX (daratumumab). DARZALEX is a CD38-directed cytolytic antibody approved for the treatment of patients with relapsed or refractory MM. Under the terms of the collaboration, Adaptive will receive an undisclosed upfront technology access payment in addition to development funding and potential future milestone payments. Adaptive will be responsible for seeking regulatory approvals for and commercialization of the clonoSEQ Assay in MM. Through this collaboration, the parties will work together to demonstrate the clinical utility of monitoring MRD negativity by the clonoSEQ Assay in MM patients who have been treated with DARZALEX, and to assess the medication's ability to achieve MRD.
Heat Biologics Selects Adaptive Biotechnologies to Discover Potential Clinical Biomarkers to Advance Novel Immunotherapies
Oct 11 16
Heat Biologics Inc. announced that they have advanced their biomarker discovery collaboration with Adaptive Biotechnologies. Adaptive will use its patented immune profiling assay, immunoSEQ™, to enable an in-depth characterization of the immune response to Heat’s ImPACT and ComPACT-based immunotherapies, including HS-410, Heat’s Phase 2 product candidate for non-muscle invasive bladder cancer. The immunoSEQ Assay, when used to evaluate the mechanism of action of the ImPACT platform, provides a significant biomarker identification opportunity to better select patients and accelerate future enrollment based on immune status.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking
Most Searched Private Companies
Sponsored Financial Commentaries